Answers are grounded in this paper and cite their sources.
The development of novel therapeutic interventions is a high-priority area of research, with a particular focus on the utilization of cell technologies. The primary impediment to the broader implementation of these technologies is the challenge of ensuring immunological compatibility with the recipient. The utilization of the patient’s own cells introduces a high degree of complexity into the process and results in an escalation in the financial burden of treatment. In certain instances, the preparation of the autologous product is constrained by the paucity of time available for its production. This review examines a number of approaches that currently exist around the world and offer the possibility of significantly reducing the time and cost of preparing cell products, thereby expanding the pool of recipients. These include the establishment of cell line banks with a known haplotype and the utilization of contemporary advancements in genome editing to generate hypoimmune cell lines. The review herein discusses the difficulties and disadvantages of each approach.
No takes yet. Share an insight, caveat, or question.
Sosnovtseva et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: